Floatz logo

Clsp-1025

Unresectable Solid Tumor

Clasp Therapeutics, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Unresectable Solid Tumor cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Medicenna Therapeutics, Inc.
Phase 1/2CC
Fmc-376
Frontier Medicines Corporation
Phase 1/2CC
Mdna11
Medicenna Therapeutics, Inc.
Phase 1/2CC
[177lu]lu-sn201
Spago Nanomedical AB
Phase 1/2CC
rc118
RemeGen Co., Ltd.
Phase 1CC

View all 20 →

Same molecule, other indications

Clsp-1025 is also rated in:

pancreatic adenocarcinomaDormant
C
Indicative ·
39 / 100
View asset →
colorectal adenocarcinomaDormant
C
Indicative ·
39 / 100
View asset →
urinary bladder carcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →